Document is current
Any future updates will be listed below
-
Authors
Lang, Frederick M. https://orcid.org/0000-0001-8866-4490
Lee, Kevin M.-C. https://orcid.org/0000-0002-6609-3524
Teijaro, John R.
Becher, Burkhard https://orcid.org/0000-0002-1541-7867
Hamilton, John A. https://orcid.org/0000-0002-9493-9224
- License Information
-
More Information
Article History
Accepted: 1 June 2020
First Online: 23 June 2020
Competing interests
: F.M.L. is a full-time employee of Roivant. Roivant is developing gimsilumab, a mAb to GM-CSF under investigation in a phase II clinical trial for the treatment of patients with COVID-19 with lung injury or ARDS. J.R.T., B.B. and J.A.H have received consulting fees from Roivant. The employer of J.A.H. and K.M.-C.L, the University of Melbourne, has licensed patented technology relating to therapeutically targeting GM-CSF to MorphoSys AG, Germany. The employer of B.B., the University of Zurich, holds a patent on the use of neutralizing GM-CSF in acute GvHD following stem cell transplantation and has a license agreement with Humanigen Inc., which is manufacturing such a GM-CSF-neutralizing mAb.
Free to read: This content has been made available to all.
